Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Predictors of major adverse cardiovascular events in patients with wild-type transthyretin amyloid cardiomyopathy: insights from a regional hospital experience
Session:
SESSÃO DE POSTERS 06 - AMILOIDOSE CARDÍACA
Speaker:
André Manuel Martins
Congress:
CPC 2025
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
17. Myocardial Disease
Subtheme:
17.2 Myocardial Disease – Epidemiology, Prognosis, Outcome
Session Type:
Cartazes
FP Number:
---
Authors:
André Manuel Faustino Martins; Joana Pereira; Mónica Amado; Adriana Vazão; Carolina Gonçalves; Mariana Carvalho; Margarida Cabral; Célia Domingues; Catarina Ruivo; Hélia Martins
Abstract
<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Introduction:</strong> Transthyretin cardiac amyloidosis (ATTR-CA) results from the deposition of amyloid fibrils in the myocardium, leading to restrictive cardiomyopathy and reduced myocardial contractile reserve. This progressive process often results in symptomatic chronic heart failure (HF) and, eventually, death.</span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Objectives:</strong> Identify predictors of extended major adverse cardiovascular events (MACE) in patients (pts) with ATTR-CA followed at a Cardiomyopathy Clinic (CC) in a regional hospital in Portugal.</span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Methods:</strong> Retrospective single-center study of pts diagnosed with wild-type ATTR-CA <span style="color:black">per</span> ESC algorithm from 2018 to 2024. Clinical, echocardiographic, electrocardiographic and analytical data were collected at the time of diagnosis (table 1). The occurrence of extended MACE, defined as cardiovascular (CV) mortality, myocardial infarction, stroke and HF hospitalizations, was assessed 18 months after diagnosis. Pts who suffered MACE (group 1) were compared with those who did not (group 2).</span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Results:</strong> 45 pts were included (80±6yrs, 91% male), of whom 20 (44%) had MACE (group 1). Group 1 pts more frequently had atrial fibrillation (AF) (95 vs 48%, p<0.001), chronic kidney disease (CKD) (80 vs 44%, p=0.014) and chronic obstructive pulmonary disease (COPD) (40 vs 12%, p=0.041). After multivariate logistic regression of these 3 comorbidities, only AF (OR 24.83, CI 95% 2.31-266.46, p=0.008) and CKD (OR 7.55, CI 95% 1.51-37.66, p=0.014) remained independent predictors of MACE. Regarding echocardiographic variables, group 1 pts demonstrated lower left atrial (LA) reservoir strain (LASr) [5.5 (IQR 3) vs 7.0% (IQR 8); p=0.039] and LA contractile strain (LASct) [0.0 (IQR 2) vs -3.0% (IQR 6); p=0.026]. Additionally, group 1 more often had atrioventricular block (40 vs 4%, p=0.012) and showed significantly higher NT-proBNP levels (5655±3006 vs 4030±2927 pg/mL, p=0.028). ROC analysis identified cut-offs for predicting MACE in ATTR-CA pts: creatinine ≥1.25 mg/dl (AUC 0.764, sensitivity (S) 85%, specificity (E) 64%), NT-proBNP ≥3220 pg/ml (AUC 0.705, S 90%, E 52%), and LASct ≥-2.5% (AUC 0.675, S 80%, E 52%). The primary driver of 18-month MACE was HF hospitalizations (86%), followed by CV mortality (14%).</span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Conclusions:</strong> In this ATTR-CA population, pts with extended MACE had lower LASr and LASct values and higher NT-proBNP levels at diagnosis. Assessing these parameters may help predict adverse outcomes. Additionally, AF and CKD were identified as independent risk factors for MACE.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site